Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 10Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Urinary Bladder Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lymphoma 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1HER-2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Gemcitabine 8Capecitabine 6pembrolizumab 5Carboplatin 5Pemetrexed 3Paclitaxel 3Oxaliplatin 3Irinotecan 3regorafenib 2osimertinib 2Taxes 2Sunitinib 2Radiotherapy 2Fluorouracil 2Cisplatin 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tislelizumab 1tegafur-gimeracil-oteracil 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1sintilimab 1seribantumab 1selinexor 1ruxolitinib 1rubitecan 1pralsetinib 1palbociclib 1olaparib 1niraparib 1linifanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma × eribulin × Clear all
NCT02404506 2021-09-29

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Swiss Cancer Institute

Phase 2 Terminated
78 enrolled
Breast

Adenocarcinoma, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡